CHI3L1 and myeloid sarcoma: However, some studies have not confirmed a correlation between the higher CHI3L1 in serum and MS clinical course [32,33,105,110], including studies by Håkansson et al., who showed the limitations of serum levels of CHI3L1 as a biomarker [97].